Table 1 Demographic and clinical characteristics of the study population
From: Prevalence of QT prolongation and its risk factors in patients with type 2 diabetes
Parameters | Mean ± SD or N (%) |
|---|---|
Total number of patients | 782 |
Age (years) | 56.4+ ± 11.8 |
Sex | |
Male | 399 (51.0%) |
Female | 383 (49.0%) |
Height (m) | 161.2 ± 9.2 |
Body weight (kg) | 82.9 ± 15.9 |
BMI (kg/m2) | 31.9 ± 5.9 |
Duration of diabetes (years) | 14.3 ± 8.7 |
HbA1c (%) | 8.7 ± 1.8 |
Systolic BP (mmHg) | 134 ± 16.9 |
Diastolic BP (mmHg) | 74.4 ± 10.2 |
Heart rate (bpm) | 83 ± 13.3 |
Fasting blood glucose (mm/L) | 9.2 ± 3.5 |
Postprandial blood glucose (mmol/L) | 13.4 ± 5.1 |
Total cholesterol (mmol/L) | 4.4 ± 1.0 |
LDL-C (mmol/L) | 2.5 ± 0.9 |
HDL-C (mmol/L) | 1.23 ± 0.5 |
Triglycerides (mg/L) | 1.6 ± 0.9 |
Retinopathy (%) | 322 (41.2%) |
Neuropathy (%) | 273 (34.9%) |
Nephropathy | 159 (20.3%) |
CVA | 15 (1.9%) |
CVD | 121 (15.5% |
PVD | 27 (3.5%) |
Hypertension | 523 (66.9%) |
Hyperlipidemia | 584 (74.7%) |
Sodium | 138.4 ± 3.1 |
Potassium | 4.2 ± 0.4 |
Antidiabetic medications | 743 (95%) |
Metformin | 623 (79.7%) |
Thiazolidinediones | 124 (15.9%) |
Sulfonylureas | 279 (35.7%) |
Meglitinides | 36 (4.6%) |
DDP-4 inhibitors | 80 (10.2%) |
Alpha-glucosidase inhibitors | 39 (5%) |
Insulin | 322 (41.2%) |
Antihypertension medications | 448 (57.3%) |
ACE inhibitors | 114 (14.6%) |
ARBs | 254 (32.5%) |
Calcium channel blockers | 134 (17.1%) |
Beta-blockers | 126 (16.1%) |
Thiazide diuretics | 107 (13.7%) |
Loop diuretics | 35 (4.5%) |
Potassium-sparing diuretics | 4 (0.5%) |
Lipid lowering medications | 512 (65.5%) |
Statins | 494 (63.2%) |
Fibrates | 25 (3.2%) |
Ezetimibe | 5 (0.6%) |
Anti-platelet medications | 501 (64.1%) |
Prolonged QTc | 102 (13%) |